{
    "2019-12-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Biogen's Shares Down on Rating Downgrade by Baird Analyst",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Shares Down",
                        "Rating Downgrade",
                        "Baird Analyst"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Where to Buy Booming Biotech ETFs",
                "features": {
                    "keywords": [
                        "Buy",
                        "Booming",
                        "Biotech ETFs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Gene-Therapy Firm Audentes Sold for Double Its Share Price. Analysts Expect More Deals.",
                "features": {
                    "keywords": [
                        "Gene-Therapy",
                        "Audentes",
                        "Sold",
                        "Double Share Price",
                        "More Deals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "gene-therapy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Astellas bets $3 billion in gene therapy deal",
                "features": {
                    "keywords": [
                        "Astellas",
                        "$3 billion",
                        "gene therapy deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "gene-therapy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}